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http://dx.doi.org/10.1016/j.ccr.2014.01.032SUMMARYClonal evolution and intratumoral heterogeneity drive cancer progression through unknownmolecular mech-
anisms. To address this issue, functional differences between single T cell acute lymphoblastic leukemia
(T-ALL) clones were assessed using a zebrafish transgenic model. Functional variation was observed within
individual clones, with a minority of clones enhancing growth rate and leukemia-propagating potential with
time. Akt pathway activation was acquired in a subset of these evolved clones, which increased the number
of leukemia-propagating cells through activating mTORC1, elevated growth rate likely by stabilizing the Myc
protein, and rendered cells resistant to dexamethasone, which was reversed by combined treatment with an
Akt inhibitor. Thus, T-ALL clones spontaneously and continuously evolve to drive leukemia progression even
in the absence of therapy-induced selection.INTRODUCTION
Cancer is an evolutionary process whereby transformed cells
continuously acquire genetic and/or epigenetic lesions to
generate functionally distinct tumor cells. Natural selection
then favors the clones with the best fitness for driving cancer
progression, therapy resistance, and relapse (Aparicio and Cal-
das, 2013). Genetic heterogeneity is increasingly recognized as
an important biomarker of cancer progression and outcome.
For example, increased tumor cell heterogeneity was recently
correlated with chemotherapy resistance in renal cell carcinoma
(Gerlinger et al., 2012) and metastasis in pancreatic adenocarci-Significance
Uncovering the consequences of acquired mutations resulting
progression and relapse. Our findings demonstrate that a subs
activation, which decreased latency, increased the frequency
mediated resistance to chemotherapy in the absence of prior
can stochastically acquire mutations necessary to survive trea
apy, with acquiredmutations being independently selected bas
that combination therapy of dexamethasone and an Akt inhib
relapsed T-ALL.
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reported in acute lymphoblastic leukemia (ALL), acute myeloge-
nous leukemia (AML), and chronic lymphocytic leukemia (CLL),
where genetic diversity within the primary leukemia was corre-
lated with an increased likelihood of drug resistance, disease
progression, and relapse (Anderson et al., 2011; Ding et al.,
2012; Landau et al., 2013; Mullighan et al., 2008; Notta et al.,
2011). While these studies have provided valuable insight into in-
tratumoral heterogeneity and patient outcome, analyses of bulk
patient samples often identifies large numbers of mutations
within a single tumor, making it difficult to determine how genetic
diversity and acquired mutations promote cancer progression.from clonal evolution will be critical for understanding tumor
et of single T-ALL cells spontaneously acquired Akt pathway
of relapse-driving leukemia-propagating cells (LPCs) and
drug exposure. These data suggest that diagnosis clones
tment and drive relapse even before a patient receives ther-
ed on important cancer phenotypes. Our work also indicates
itor can successfully kill LPCs in a subset of refractory and
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Clonal Evolution Drives T-ALL ProgressionUnderstanding the consequences of genetic heterogeneity
necessarily require detailed functional analysis of multiple single
cells contained within the same primary tumor.
Recent advances in genomic technologies have provided
unique insights into the clonal relationships between cancer cells
and in some cases have documented the order by which genetic
changes accumulate following progression and relapse. For
example, the clonal relationship between primary and relapsed
ALL was identified using copy number aberration analysis in
matched patient samples. Continued clonal evolution and acqui-
sition of de novo mutations occurred in a majority of relapse
samples (Clappier et al., 2011; Mullighan et al., 2008), with
most relapse disease arising from the evolution of an underrep-
resented clone contained within the primary leukemia. Whole
genome sequencing studies have revealed that AML also
undergoes clonal evolution from diagnosis to relapse, with five
of eight patients developing relapse from a genetically distinct,
minor clone that survived chemotherapy (Ding et al., 2012).
Finally, 60% of CLL exhibited continued clonal evolution, where
high clonal heterogeneity in the primary leukemia was associ-
ated with disease progression and prognosis (Landau et al.,
2013), suggesting that clonal evolution is common and likely
an important driver of cancer progression. While these studies
have detailed lineage relationships between leukemic clones
and often identified genetic lesions correlated with progression
and relapse, the functional effects of these mutations have not
been fully assessed.
Cancer progression and relapse are driven by distinct and
often-rare cancer cells referred to as tumor-propagating cells,
or in blood cancers as leukemia-propagating cells (LPCs). If
LPCs are retained following treatment, they will ultimately initiate
relapse disease (Clarke et al., 2006). Despite the substantial
number of genetic lesions that have been identified in relapse
samples and the contention that these mutations likely modulate
response to therapy, acquired mutations that increase the over-
all frequency of tumor-propagating cells following continued
clonal evolution at the single cell level have not been reported.
Such mutations would increase the pool of cells capable of
driving continued tumor growth and progression, thereby
increasing the likelihood of relapse. Although we have previously
found that LPC frequency can increase in a given leukemia over
time (Smith et al., 2010), it is unclear whether this was the result
of continued clonal evolution or if a clone with inherently high
LPC frequency simply out competed other cells within the
leukemia.
T-ALL is an aggressivemalignancy of transformed thymocytes
with an overall good prognosis. Yet despite major therapeutic
improvements for the treatment of primary T-ALL, a large frac-
tion of patients relapse from retention of LPCs following therapy,
often developing leukemia that is refractory to chemotherapies
including glucocorticoids (Einsiedel et al., 2005; Pui et al.,
2008). Importantly, T-ALL exhibits clonal evolution at relapse,
suggesting that this process is an important driver of therapy
resistance, enhanced growth and leukemia progression (Clap-
pier et al., 2011; Mullighan et al., 2008). Primary T-ALL is charac-
terized by changes in several molecular pathways, including
mutational activation of NOTCH and inactivation of CDKN2A,
FBXW7, and PTEN (Van Vlierberghe and Ferrando, 2012). The
Myc pathway is also a dominant oncogenic driver in vastmajorityof human T-ALL, resulting in part from NOTCH1 pathway activa-
tion (Palomero et al., 2006). Myc has also been recently shown to
be a critical regulator of T-ALL progression (King et al., 2013),
suggesting that identifying collaborating genetic events that
synergize with Myc to enhance LPC frequency, leukemic cell
growth, and resistance to therapy will likely be important to
understanding human disease.
RESULTS
Continued Clonal Evolution Generates Subclonal
Variation to Enhance LPC Frequency and Shorten
Disease Latency
To gain insight into the functional role that tumor heterogeneity
has on leukemia-propagating potential and latency, a cell trans-
plantation-based screen was completed in which syngeneic
zebrafish were engrafted with single, fluorescently labeled
clones isolated from primary Myc-induced T-ALL (Figure 1A).
This approach mimics the process by which a single cell can re-
initiate leukemia at relapse. Importantly, zebrafish Myc-induced
T-ALL are molecularly similar to the subset of human T-ALL that
expresses SCL and LMO2, mimicking an aggressive and com-
mon form of human disease (Blackburn et al., 2012; Langenau
et al., 2005). Moreover, zebrafish Myc-induced T-ALL is hetero-
geneous and is often comprised of numerous clones that harbor
unique T cell receptor beta (tcrb) rearrangements, making it the
ideal system with which to define the functional effects of
intratumoral heterogeneity and clonal evolution. Myc-induced
leukemias were generated to express a variety of fluorescent
proteins including AmCyan, GFP, zsYellow, dsREDexpress,
and mCherry. The monoclonality of each transplanted T-ALL
was confirmed by genomic DNA analysis of tcrb rearrangements
(Table S1 available online) and comparative genomic hybridiza-
tion arrays (aCGH). Each monoclonal, primary transplanted
T-ALL was then assessed for differences in latency, determined
as the time required for >50% of the animal to be overtaken by
fluorescently labeled T-ALL and in the overall frequency of
relapse-driving LPCs, as determined by limiting dilution trans-
plantation into syngenic recipients (Figure 1A). Sort purity
following FACS ranged from 87%–98% and viability was >95%
for all analyses. In total, 47 primary transplanted, fluorescently
labeled monoclonal T-ALL were derived from 16 different
primary leukemias.
Array CGH analysis revealed that clones from the same leuke-
mia often shared common focal amplifications and deletions
irrespective of tcrb rearrangement status. For example, all four
clones from T-ALL #1 shared regional losses within chr1 and
identical gains in chr2, chr7, chr12, chr14, and chr25, despite
harboring different tcrb rearrangements (Figure S1A). Clones
had additional genetic changes that were specific to each sub-
clone, suggesting that zebrafish T-ALL clones were derived
from a common ancestor and had undergone a branched evolu-
tion similar to that found in human patients (Mullighan et al.,
2008) (Figures S1A and S1B). Clones isolated from the same pri-
mary T-ALL also commonly had different functional phenotypes.
From primary T-ALL #1, clone 1.1 harbored a V15C1 tcrb rear-
rangement and generated leukemias that contained 1 LPC for
every 12 cells. By contrast, clone 1.4 was genetically distinct
with a V17C2 rearrangement and had a significantly lower LPCCancer Cell 25, 366–378, March 17, 2014 ª2014 Elsevier Inc. 367
Figure 1. Clonal Evolution Drives Intratumoral Heterogeneity and Can Lead to Increased Leukemia Propagating Cell Frequency
(A) A schematic of the cell transplantation screen designed to identify phenotypic differences between single leukemic clones.
(B and C) Schematic of results from primary T-ALL #1 (B) and T-ALL #9 (C). *Denotes a significant increase in LPC frequency from monoclonal primary to
secondary transplant (p = 0.02). **Denotes a significant increase in LPC frequency frommonoclonal primary transplant T-ALL comparedwith tertiary transplanted
leukemia (p < 0.0001). Clones are color-coded based on tcrb-rearrangements.
See also Figure S1 and Table S1.
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Clonal Evolution Drives T-ALL Progressionfrequency of 1 in 419 cells (p < 0.0001, Figure 1B; Table 1; Table
S1). Functional variation was also observed within related
clones. For example, clones 1.2 and 1.3 had the same V36C1 re-
arrangement, but had an 17-fold difference in the overall
numbers of LPCs (p < 0.0001), suggesting that continued
clonal evolution resulted in increased LPC function and fre-
quency. Finally, individual clones isolated from T-ALL #1 also
had significant differences in latency, with the median time to
T-ALL onset ranging from 27 to 58 days in transplant animals
(Figure 1B; Table S1, p < 0.01). In total, functional variation
between single clones was documented in 13 of 16 the pri-
mary T-ALL examined (Figures 1B, 1C, and S1B; Table S1), indi-
cating that functional heterogeneity between leukemic clones is
common.
To directly assess if continued clonal evolution can impart
functional consequences to LPC frequency and latency, T-ALL
generated from single cells were serially passaged at limiting
dilution and recipient animals assessed for changes in time to
leukemia regrowth and overall LPC frequency (n = 3,767 trans-
plant animals assessed). From this analysis, 6 of 47 clones
underwent continued clonal evolution that resulted in an average
20-fold increase in LPC frequencywhen comparedwith the initial
monoclonal, primary transplanted T-ALL (range: 7- to 30-fold,368 Cancer Cell 25, 366–378, March 17, 2014 ª2014 Elsevier Inc.Figures 1B and 1C; Table 1). For example, clone 1.4 had an
LPC frequency of 1:419, which increased following serial
passaging to 1:16 (Figure 1B; Table 1). Further, two clones simul-
taneously evolved both elevated LPC frequency and reduced la-
tency following serial passaging (clones 10.1 and 14.1, Table 1).
Outgrowth of a contaminating clone was excluded in all cases by
analysis of tcrb rearrangements. The remaining 41 clones had no
significant change in latency or LPC frequency following serial
passaging (Table S1). Together, these data indicate that
continued clonal evolution occurs in a small subset of T-ALL
clones and can lead to spontaneous changes within single cells
to alter both LPC frequency and latency.
Independent Pathways Can Regulate LPC Frequency
and Growth Rate
In analyzing the functional differences between clones and the
subclonal variation acquired following serial passaging, we
found that LPC frequency and latency often evolve indepen-
dently, suggesting that these processes can be regulated by
different molecular mechanisms (Table S1). To confirm this
observation, equal numbers of LPCs from selected clones
were transplanted into recipient fish, and time to leukemia re-
growth was assessed. From this analysis, we confirmed that
Table 1. Summary of Clones that Evolved Increased LPC Frequency
T-ALL
Limiting Dilution Transplanta
LPC Frequencyb Latency (days)c1,000 Cell 100 Cell 10 Cell
Primary 1 7/8 3/20 2/38 1:462 (871, 245) >180
Clone 1.4
Primary transplant 4/5 2/8 1/17 1:419 (1,050, 167) 27.1 ± 2.1
Secondary transplant 5/5 4/8 2/11 1:111 (259, 49) 26.8 ± 2.2
Tertiary transplant 5/5 8/8 5/11 1:16 (36, 7)** 27.1 ± 2.1
Primary 6 5/5 9/18 6/45 1:114 (193, 67) 45
Clone 6.1
Primary transplant 5/5 4/10 1/15 1:182 (417, 79) 43.0 ± 2.4
Secondary transplant 3/3 6/6 3/10 1:25 (58, 10) 53.4 ± 2.9
Tertiary transplant 3/3 6/6 6/20 1:26 (57, 13)*** 45.0 ± 3.0
Primary 8 4/5 5/34 5/82 1:447 (793, 251) 115
Clone 8.4
Primary transplant 3/3 2/6 2/10 1:267 (786, 91) 35.0 ± 3.1
Secondary transplant 2/2 5/6 3/10 1:43 (88, 19) 38.5 ± 2.4
Tertiary transplant 2/2 6/6 7/11 1:9 (21, 5)** 33.3 ± 1.8
Primary 9 5/5 8/26 4/52 1:219 (378, 126) 98
Clone 9.3
Primary transplant 4/4 3/6 1/12 1:136 (365, 50) 47.8 ± 2.2
Secondary transplant 2/2 4/6 2/8 1:70 (171, 29) 50.2 ± 2.8
Tertiary transplant 2/2 5/5 6/10 1:11 (24, 4)** 37.6 ± 2.9
Primary 10 5/5 6/20 3/42 1:225 (418, 121) 49
Clone 10.1
Primary transplant 3/3 2/6 0/10 1:263 (780, 88) 78.4 ± 4.1
Secondary transplant 3/3 6/6 4/9 1:16 (42, 7)** 32.7 ± 2.0
Tertiary transplant 3/3 6/6 3/9 1:22 (58, 9)** 32.2 ± 1.5#
Primary 14 6/7 5/36 3/72 1:509 (892, 290) 82
Clone 14.1
Primary transplant 3/3 1/5 0/10 1:356 (1,101, 115) 63.0 ± 2.9
Secondary transplant 3/3 4/6 2/10 1:74 (177, 31) 51.3 ± 4.3
Tertiary transplant 2/2 5/5 5/9 1:12 (25, 5)** 37.1 ± 2.7##
aThe number of engrafted animals over the number of total animals transplanted at each dose.
bThe 95%confidence interval for LPC frequency is shown in parenthesis. Clones that increased the overall fraction of LPCs following serial passage are
indicated. **p < 0.0001; ***p = 0.0003.
cData are presented with ±SE where applicable. Clones that exhibited diminished latency from the primary to tertiary transplantation are noted.
#p < 0.0001; ##p = 0.016.
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in time to leukemia onset (Figure 2A). Analysis of all serially
passaged clones revealed no significant correlation between
LPC frequency and latency (n = 120, Figure 2B). 5-Ethynyl-2’-de-
oxyuridine (EDU) incorporation (Figure 2C) and phospo-H3 stain-
ing (data not shown) showed that proliferation rate correlated
with time to leukemia regrowth in vivo, but did not correlate
with overall LPC frequency. Apoptosis rates did not differ be-
tween clones (Figures S2A and S2B). Together, these data sug-
gest that the pathways that regulate T-ALL latency/proliferation
and LPC frequency need not be controlled by the same molecu-
lar mechanism; rather they can be evolved independently in a
subset of T-ALL clones.
To directly assess which of these processes dominate in
driving T-ALL progression, in vivo competition experimentswere performed between clones that exhibited inherent dif-
ferences in latency and LPC frequency and differed in
fluorescent protein expression. In each experiment, recipient
fish were transplanted with 25 LPCs from two fluorescent
clones and leukemia growth was assessed at 15 and
45 days posttransplantation. T-ALL clones with short latencies
but low LPC frequency consistently out competed clones with
longer latencies but high LPC frequency (Figures 2D and 2E).
These data suggest that although leukemia propagating
potential is required to reinitiate disease, clones with high
proliferative capacity likely out compete other cells during dis-
ease progression and relapse. Moreover, these data support
our conclusion that T-ALL latency and leukemia-propagating
potential need not be regulated by the same molecular
mechanisms.Cancer Cell 25, 366–378, March 17, 2014 ª2014 Elsevier Inc. 369
Figure 2. Mechanisms that Drive Leukemia
Propagating Cell Frequency and Latency
Can Evolve Independently
(A) Fish were transplanted with 25 LPCs from
various clones and assessed for time to leukemia
onset (n = 8–10 animals transplanted per individual
clone). *Denotes significant differences in latency
between clones that have low (upper left panel) or
high (lower left panel) LPC frequencies (<0.001).
Representative fluorescent images of animals
following 28 days of engraftment are shown.
(B) Correlation between LPC frequency and T-ALL
latency across all clones.
(C) EDU analysis of selected clones and correlation
with LPC frequency and latency. Each datum point
represents a single clone. NS, not significant.
**Denotes a significant difference in the percent of
cells that are EDU-positive (p = 0.0004).
(D) Animals were transplanted with 25 LPCs from
clone 11.2 (dsRED-positive, 1:78 LPC frequency,
88 days latency) and 25 LPCs from clone 4.3 (GFP-
positive, 1:246 LPC frequency, 28 days latency).
Representative images of whole fish and confocal
images of T-ALL cells harvested at 15 days and
45 days posttransplantation. The percentages of
dsRED-positive and GFP-positive cells at 15 days
and 45 days were analyzed by FACS. Data are
represented as ± SE (n = 4–7 transplant recipients
per time point).
(E) Twenty-five LPCs from clone 1.3 (zsYellow-
positive, 1:13 LPC frequency, 58 days latency) were
competed with 25 LPCs from clone 5.1 (amCyan-
positive, 1:184 LPC frequency, 30 days latency),
and analyzed as in (D). Scale bars represent 5 mm in
images of whole fish and 40 mm in confocal images.
See also Figure S2.
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Growth
We next performed a series of competition experiments to deter-
mine whether clones within a heterogeneous leukemia could
functionally impact the LPC frequency and/or latency of other,
genetically distinct clones. Clones that had different functional
properties and labeled with different fluorescent proteins were
transplanted into recipient animals at limiting dilution and
assessed for the ability to alter the cellular fate of cotransplanted
T-ALL cells. In the first set of experiments (Figure 3A), fluores-
cently labeled clones with high LPC frequency and short
latencies were cotransplanted with clones that had low LPC
frequency and long latencies. After T-ALL formation, fluorescent
T-ALL cells were isolated from recipient fish by FACS (>94%
purity and >98% viability) and transplanted at limiting dilution.
Mixing had no long-term effect on altering LPC frequency (Fig-370 Cancer Cell 25, 366–378, March 17, 2014 ª2014 Elsevier Inc.ure 3B) or latency (Figure 3C) in any clone
tested. Next, we determined if continuous
juxtacrine or paracrine signaling from
clones with high LPC frequency was
necessary to alter the frequency of LPCs
in clones with low leukemia propagating
potential. Specifically, T-ALL clones with
high LPC frequency were transplanted
into recipient fish and allowed to engraftfor 7 days. Engrafted animals were then transplanted at limiting
dilution with a clone with low LPC frequency (Figure S3A).
Animals were assessed for engraftment of the second clone at
45 days, and again, cell extrinsic signaling from clones with
high LPC frequency did not impart elevated leukemia propa-
gating potential to cells with low LPC frequency (Figure S3B).
These data show that cell autonomous processes regulate
growth kinetics and overall frequency of LPCs in most T-ALL
clones.
Clonal Evolution Can Activate Akt Signaling to Increase
Both LPC Frequency and Growth in T-ALL
Although our data suggest that increased LPC frequency and
growth rate can be acquired in clones through independent
mechanisms, mutations in genes and pathways that simulta-
neously enhance both of these processes would likely be
Figure 3. LPC Frequency and Latency Are Regulated Cell-Autono-
mously in T-ALL
(A) Schematic of the experimental design.
(B) Summary of results with 95% confidence intervals shown in parenthesis.
xIndicates an independent limiting dilution cell transplantation experiment
confirming similar results as those shown in Table S1.
(C) Kaplan-Meier analyses of leukemia regrowth in animals transplanted with
individual clones alone or following mixing. Tumor-negative animals were
excluded from analysis.
See also Figure S3.
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Clonal Evolution Drives T-ALL Progressionselected for within a heterogeneous leukemia. Thus, we com-
pleted a systematic genetic analysis to identify the pathways
associated with elevated LPC frequency and reduced latency.
We did not identify shared, recurrent genetic amplifications or
deletions among the clones that had evolved high LPC fre-
quency following serial passaging (n = 5 clones analyzed by array
CGH at both primary and tertiary transplant). We next analyzed
45 of 47 monoclonal primary transplanted T-ALL for recurrent
point mutations common to human T-ALL pathogenesis, in-
cluding six paired samples that consisted of a primary mono-
clonal transplanted T-ALL with low LPC frequency and the
matched tertiary transplant that had evolved high LPC fre-
quency. In total, notch1b, il7r, akt2, akt3, n-ras, h-ras, k-ras,
fbxw7, ptpn11a, pik3ca, pikr1, pten-a, and pten-b were as-
sessed for known hotspot mutations in human T-ALL. Although
we observed notch1 mutations in several clones (11 of 44),
they were not exclusively associated with clones that had high
LPC frequency, consistent with our previous report that acti-
vated Notch signaling does not elevate LPC frequency in Myc-
driven T-ALL (Blackburn et al., 2012). Moreover, most notch1
mutations did not occur within the amino acid residues knownto alter protein stability or lead to constitutively active Notch
signaling (Table S2). Genetic alterations in other genes were
not detected (Table S2).
Because our data suggested that both genetic and epigenetic
modifications likely play a role in clonal evolution (Figures S4A
and S4B), we next assessed clones with high LPC frequency
for changes in the expression of a wide range of genes impli-
cated in human T-ALL (Figure S4C; Table S3). Endogenous
myc-a, myc-b, or transgenic Myc expression were not altered
following serial transplant, obviating the possibility that Myc
transcript levels accounted for phenotypic changes in LPC
frequency and/or latency in the Myc-induced zebrafish model
(Figure S4C). Additionally, expression of genes that have been
previously linked to T-ALL proliferation and self-renewal, includ-
ing the Notch target gene hes1, lmo2, and tal1 (McCormack
et al., 2010; Van Vlierberghe and Ferrando, 2012), were not
elevated in clones with high LPC frequency. In contrast, genes
known to regulate the Akt pathway were frequently misex-
pressed in clones with high LPC frequency (Table S3). For
example, serially passaged clone 8.4 had acquired elevated
expression of n-ras and h-ras, clone 10.1 increased expression
of ptpn11, and clone 14.1 lost expression of both pten-a and
pten-b (Figure S4C; Table S3).
Based on these findings, we next assessed whether activation
of the Akt pathway was directly associated with high LPC fre-
quency. Immunohistochemistry (IHC) showed that 11 of 19
monoclonal T-ALL with high LPC frequency expressed high
levels of phosphorylated Akt (pAkt), while only 1 of 26 clones
with low LPC frequency exhibited pAkt staining (Figures 4A
and S4D). Western blot analysis confirmed IHC results for the
subset of clones analyzed (Figure S4E). Additionally, three of
six T-ALL clones showed a marked increase in pAkt staining
following continued clonal evolution, concurrent with an increase
in LPC frequency (Figure 4B). These same clones had exhibited
robust gene expression changes associated with activation of
the Akt pathway, noted above (clones 8.4, 10.1, and 14.1, Fig-
ure S4C). Acquired Akt activation in these evolved clones was
confirmed by western blot analysis for phosphorylation of Akt
at serine 473 and phosphorylation of the downstream target
S6-kinase (S6K, Figure 4C). Interestingly, treatment of evolved
clone 10.1 with the epigenetic modifying drugs 5-azacytadine
and sodium butyrate reduced LPC frequency and eliminated
Akt signaling (Figures S4B and S4F), suggesting that the Akt
signaling pathway can be regulated by epigenetic mechanisms
and likely plays a functionally important role in regulating the
overall numbers of LPCs in T-ALL.
To assess if clones had become dependent on Akt signaling
for growth and LPC function in vivo, zebrafish were transplanted
at limiting dilutionwithmonoclonal primary transplant clone 10.1,
which had low LPC frequency and was pAkt-negative, or tertiary
transplant clone 10.1, which concurrently evolved high LPC fre-
quency and pAkt-positivity. Transplanted animals were immedi-
ately placed in water containing DMSO or MK2206, an allosteric
inhibitor of Akt, at a dose that effectively reduced phosphoryla-
tion of both Akt and S6K in vivo (Figure S4G). Zebrafish received
drug treatment for 5 days, and transplanted animals were subse-
quently followed for altered LPC frequency (Figure 4D) and
T-ALL latency (Figures 4E–4G). MK2206 treatment had no effect
on modulating LPC frequency or latency in clone 2.2, whichCancer Cell 25, 366–378, March 17, 2014 ª2014 Elsevier Inc. 371
Figure 4. Akt Pathway Activation Is Acquired by a Subset of Cells following Clonal Evolution and Drives Elevated LPC Frequency and Growth
(A) Graphical summary of pAkt(S473) IHC from 46monoclonal T-ALL. Green denotes samples that are pAkt-positive, and black have low or absent pAkt staining.
Triangles represent clones that were confirmed for pAkt status by western blot analysis. The vertical dotted line demarcates clones with short (<45 days) or long
latencies, and the horizontal dotted line identifies clones with low (<1.0%) or high LPC frequency. pAkt-positivity is significantly associated with high LPC fre-
quency (p < 0.0001) and short latency (p = 0.017) by Fisher’s exact test.
(B) IHC analysis of pAkt staining in T-ALL clones. Scale bar represents 50 mm.
(C) Western blot analysis of selected clones from (B).
(D) Animals were transplanted with the clones indicated and treated withMK2206 or DMSO for 5 days. Representative images at 28 days posttransplantation with
LPC frequencies noted. *Denotes a significant change in LPC frequency following MK2206 treatment (p < 0.001). Scale bar represents 5 mm.
(E–G) Kaplan-Meier analyses for T-ALL regrowth following DMSOorMK2206 treatment for clone 2.2 (E), primarymonoclonal transplant clone 10.1 (F), and tertiary
transplant clone 10.1 (G). **Denotes a significant change in T-ALL latency following MK2206 treatment (p < 0.0001).
See also Figure S4, Table S2, and Table S3.
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Figure 5. The Akt Pathway Increases LPC Frequency through DownstreamActivation ofmTORC1 and Shortens Latency by AugmentingMyc
Stability
(A) Representative images of zebrafish that were transplanted with 25 LPCs from T-ALL expressing GFP and the indicated constructs (three T-ALL per genotype,
n = 35 animals transplanted per primary leukemia) at 28 days posttransplantation.
(B) Kaplan-Meier analyses of time to T-ALL regrowth for each genotype and compared toMyc alone expressing T-ALL. *Denotes a significant difference in latency
of p < 0.0001. **Indicates a significant difference in latency of p = 0.003.
(C) EDU analysis of transgenic T-ALL. Each datum point represents the percent EDU-positive cells for one T-ALL. xRepresents a significant difference of
p < 0.0001. xxDenotes a significant difference of p = 0.004, when compared to Myc alone expressing T-ALL. NS, no significant difference.
(D) Graph showing LPC frequency within each transgenic group. Each point represents data for one primary T-ALL. #Denotes a significant difference in LPC
frequency of p < 0.0001. ##Indicates a significant difference in LPC frequency of p = 0.0025 when compared to Myc alone expressing T-ALL. NS, no significant
difference.
(E) Western blot analysis.
See also Figure S5 and Table S4.
Cancer Cell
Clonal Evolution Drives T-ALL Progressionexhibited high LPC frequency but lacked Akt pathway activation,
or in the pAkt-negative primary monoclonal transplanted clone
10.1. However, MK2206 treatment reduced the overall fre-
quency of LPCs by 25-fold in evolved, pAkt-positive clone
10.1, reverting it to a similar LPC frequency and latency as its
pAkt-negative ancestral clone (Figures 4D, 4F, 4G and S4H).
Importantly, 15 of 17 zebrafish transplanted with pAkt-positive
serially passaged clone 10.1 and treated with DMSO developed
T-ALL, while only 11 of 21 zebrafish treated with the MK2206
developed T-ALL (p = 0.034, Fisher’s exact test, Figure S4H).
These data suggest that the Akt inhibitor not only reduced LPC
frequency, but also efficiently killed LPCs, and provides further
evidence that Akt plays an important role in LPC function.
Akt Pathway Activation Enhances the Frequency of
LPCs through mTORC1
To provide conclusive genetic evidence that Akt signaling en-
hances LPC frequency, transgenic zebrafish were generated
that expressed (1) rag2:Myc + rag2:GFP, (2) rag2:Myc + rag2:
myristoylated-Akt2 (myr-Akt2) + rag2:GFP, or (3) rag2:myr-
Akt2 + rag2:GFP. The myristoylated-Akt2 transgene leads to
constitutive activation of Akt signaling in theMyc-induced zebra-
fish T-ALL model (Gutierrez et al., 2009) and significantly
enhanced time to primary T-ALL onset when compared to
Myc-alone expressing T-ALL (25 ± 4 days compared with 62 ±17 days, Figures S5A and S5B). In contrast, zebrafish that ex-
pressed only rag2:myr-Akt2 failed to develop T-ALL over the
180 days of observation (n = 7) and are in agreement with earlier
work indicating that Akt signaling induces T-ALL in zebrafishwith
very low penetrance (Gutierrez et al., 2011). Upon transplanta-
tion of 25 LPCs, T-ALL that expressed both Myc and myr-Akt2
reformed leukemia 35 days faster than those that expressed
Myc alone (Figures 5A and 5B), likely due to a substantial in-
crease in proliferation in Myc + myr-Akt2 cells (Figure 5C).
Constitutive Akt signaling also increased the overall LPC fre-
quency by an average of 5.8-fold when compared to those that
expressed only Myc (Figure 5D; Table S4). Activation of the Akt
pathway by the myr-Akt2 transgene was verified by western
blot analysis for phosphorylated Akt and S6K (Figure 5E). Impor-
tantly, constitutive activation of Akt also shortened latencies in
both primary and transplant T-ALL in the notch1aICD-induced
zebrafish model (Figures S5C and S5D) and significantly
increased the LPC frequency by 12-fold when compared to
notch1aICD-alone expressing T-ALL (Figure S5E; Table S4),
demonstrating that the Akt pathway can synergize with multiple
oncogenes to enhance LPC frequency.
To rapidly identify candidate molecular pathways acting
downstream of Akt that are required for continued T-ALL main-
tenance and growth, monoclonal T-ALL were treated ex vivo
with inhibitors to various Akt target pathways. All pAkt-positiveCancer Cell 25, 366–378, March 17, 2014 ª2014 Elsevier Inc. 373
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hibitors Torisel and rapamycin, but not with b-catenin or NF-kb
pathway inhibitors (Figure S5F). These compounds had no effect
on the pAkt-negative clones. Efficacy of Torisel in blocking S6K
phosphorylation was verified by western blot analysis (Fig-
ure S5G). Based on this data, transgenic zebrafish were gener-
ated that overexpressed constitutively active RHEB(Q64L),
which specifically activates the mTORC1 pathway (Jiang and
Vogt, 2008). Akt is also known to stabilize the Myc protein
through downregulation of GSK-3b, preventing phosphorylation
of Myc at threonine 58 and blocking its degradation through the
ubiquitin/proteasome pathway (Bonnet et al., 2011). Addition-
ally, we had observed that a subset of pAkt-positive clones over-
expressed the Myc target genes ocd1, cd25a, and cad, without
concurrent increase in transgenic or endogenousMyc transcript
levels (Figure S4C; Table S3), suggesting that Myc protein may
be stabilized in these cells. Therefore, zebrafish T-ALL were
also generated that overexpressed Myc(T58A), a mutant that is
inefficiently degraded by the proteasome and mimics the effects
of pAkt stabilization. Zebrafish expressing either rag2:Myc +
rag2:RHEB(Q64L) + rag2:GFP and rag2:Myc(T58A) + rag2:GFP
developed early onset primary T-ALL when compared with ani-
mals that expressed only rag2:Myc + rag2:GFP (Figures S5A
and S5B). Importantly, rag2:RHEB(Q64L) + rag2:GFP animals
did not develop T-ALL over 180 days of observation, indicating
that mTORC1 activation alone may not be sufficient for T-ALL
formation (n = 9).
To assess the effects of pAkt regulated pathways on leukemia
regrowth and LPC frequency, T-ALL cells from each genotype
were transplanted at limiting dilution and assessed for time to
leukemia onset or overall LPC frequency. T-ALL expressing
Myc(T58A) reinitiated leukemia 19 ± 4.3 days faster thanMyc-ex-
pressing T-ALL, whileRHEB(Q64L) overexpression had no effect
on latency (Figures 5A and 5B). Similarly, Myc(T58A) but not
RHEB(Q64L) T-ALL cells were significantly more proliferative
than Myc-induced T-ALL (Figure 5C). Apoptosis rates did not
differ between any transgenic T-ALL (Figure S5H), suggesting
that proliferation rather than apoptosis rates are largely respon-
sible for differences in latency. Limiting dilution cell transplanta-
tion experiments revealed that stabilized Myc(T58A) had no
effect on LPC frequency. By contrast, RHEB(Q64L) expression
significantly enhanced LPC frequency by an average of 4-fold
when compared toMyc-alone expressing leukemias (Figure 5D;
Table S4). Phosphorylation of S6K and expression of Myc target
genes were verified in all transgenic T-ALL analyzed (Figures 5E
and S5I). No overt differences in morphology and T-ALL molec-
ular subtype were observed between any transgenic T-ALL (Fig-
ures S5J and S5K). These data show that the Akt signaling may
act through two independent downstream pathways to increase
T-ALL growth, likely by stabilizing Myc protein to enhance prolif-
eration rates, and to increase the overall frequency of LPCs
through activation of mTORC1.
Akt Activation following Clonal Evolution Also Renders
Cells Resistant to Glucocorticoid Therapy
Treatment of T-ALL with the glucocorticoid dexamethasone
often leads to acquired drug resistance in patients, which can
be partly attributed to PTEN loss and activation of the Akt
pathway (Beesley et al., 2009; Piovan et al., 2013; Schult et al.,374 Cancer Cell 25, 366–378, March 17, 2014 ª2014 Elsevier Inc.2012; Silva et al., 2008). Based on these reports, we questioned
if T-ALL clones spontaneously developed dexamethasone resis-
tance following clonal evolution and activation of the Akt
signaling pathway. Indeed, ex vivo drug treatment showed that
the three T-ALL clones that were pAkt-negative as primary
monoclonal T-ALL were killed by dexamethasone, while these
same clones had become refractory to glucocorticoid-induced
cell killing following clonal evolution and Akt pathway activation
(Figure 6A). Combined treatment with either the Akt inhibitor
MK2206 or the PIK3C inhibitor PI103 resensitized pAkt-positive
clones to dexamethasone-induced killing (Figures 6A and S6A),
suggesting that inhibition of Akt is responsible for the reduced
viability of these clones. Similar results were also obtained using
additional pAkt-positive and pAkt-negative primary monoclonal
transplant clones (Figure S6B) and human T-ALL cells (Fig-
ure 6B), where pAkt status predicted a reduced response to
dexamethasone-induced killing, which could be restored with
the addition of MK2206 (Chan et al., 2007; Palomero et al.,
2007). Finally, drug combinations were also tested in vivo.
Similar to the ex vivo results, dexamethasone treatment killed
T-ALL in animals transplanted with pAkt-negative, primary
monoclonal transplant clone 14.1, but the evolved, pAkt-positive
cells were largely refractory to treatment (Figure 6C). The pAkt-
positive T-ALL was effectively killed by the combination of dexa-
methasone and MK2206, resulting in almost complete T-ALL
regression. These experiments provide evidence that an Akt in-
hibitor can resensitize refractory T-ALL cells to dexamethasone-
induced killing in vivo and demonstrate that T-ALL clones can
spontaneously develop resistance to chemotherapy as a result
of clonal evolution and that this can occur without selection
induced by prior drug exposure.
DISCUSSION
The transformation from a normal to a tumorigenic cell is gener-
ally thought to follow a Darwinian evolutionary model, ultimately
culminating in clonal evolution producing tumor cells that are
well-adapted to proliferate and to overcome the selective pres-
sures of metabolic stress, hypoxia, radiotherapy, and chemo-
therapy (Gerlinger and Swanton, 2010). In response to therapy,
established cancers can continue to amass genetic and epige-
netic lesions to enhance their propensity to form relapse. In sup-
port of this theory, genetic heterogeneity has been described in
most cancer types and continued clonal evolution at relapse has
been documented in several cancers. Moreover, heterogeneity
has been correlated with important clinical features including
progression, therapy resistance, and relapse (Almendro et al.,
2013; Gerlinger and Swanton, 2010). Although the acquisition
of genetic mutations at relapse has been well described, few
studies have documented continued clonal evolution in the
absence of therapy and the spontaneous acquisition of drug-
resistant clones. For example, untreated chronic lymphocytic
leukemias exhibit continued clonal evolution, ultimately resulting
in spontaneous acquisition of genetic lesions that impart drug-
resistance (Landau et al., 2013). However, these studies failed
to correlate clonal evolution with specific features of progres-
sion, including shortened latency and enhanced LPC frequency,
nor did they identify mechanistic drivers responsible for therapy
resistance following continued clonal evolution. Our work follows
Figure 6. Dexamethasone Resistance Is Acquired following Akt Pathway Activation in Clonally Evolved Cells and Can Be Overcome by
Combined Treatment with MK2206
(A) Primary monoclonal T-ALL that were pAkt-negative (red) and tertiary transplanted T-ALL that were pAkt-positive (green) were treated ex vivo as indicated and
assessed for viability (n = 6 replicates per clone). Error bars are ± SE.
(B) Human cell lines with (green) or without (red) active Akt signaling were treated in vitro as indicated. Each point is the average viability after 24 hr of drug
treatment (n = 3 replicates per cell line). Error bars ± SE.
(C) Representative images of leukemic fish prior to or 4 days after drug treatment with DMSO, 350 mg/l dexamethasone, 3.5 mM MK2206, or 350 mg/l
dexamethasone + 3.5 mMMK2206. Clone name and pAkt status are shown to the left. Waterfall plots at the bottom summarize the in vivo T-ALL responses. Each
bar denotes the percent change in T-ALL burden within a single animal, those with diagonal lines indicate >50% reduction in T-ALL burden.
See also Figure S6.
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Clonal Evolution Drives T-ALL Progressionclonal evolution within single leukemic cells and directly associ-
ates functional consequences of clonal evolution with specific
cellular features including therapy resistance. Moreover, we
have discovered key oncogenic pathways responsible for
changing the cellular phenotypes of leukemic cells following
clonal evolution.
Utilizing the zebrafish transgenic T-ALL model and large-scale
cell transplantation experiments, leukemias were generated
from single LPCs isolated from heterogeneous primary T-ALL
samples. This process of single cell cloning effectively created
a homogenous background in which additional mutational
events could be readily identified and directly associated with
cellular phenotype. This large-scale screen allowed us to answer
fundamental questions regarding the role that tumor cell hetero-
geneity has in cancer progression at the single cell level. First, we
found that continued clonal evolution reduced latency, increased
the frequency of LPCs, and modulated chemotherapy resis-
tance, all of which can contribute to disease progression and
relapse. These processes were independently evolved in a sub-
set of T-ALL clones, yet in others, they were coevolved simulta-
neously through activation of the Akt signaling pathway. Our
data suggest that multiple, parallel pathways can modulate
each of these processes within a single leukemic cell. Addition-
ally, while it is widely recognized that LPCs are required for
malignancy and relapse (Clarke et al., 2006), a role for continued
clonal evolution in enhancing the overall frequency of LPCs
has gone largely unreported. In vivo competition experiments
further suggest that mechanisms regulating LPC frequency
and latency are regulated cell autonomously, without influence
from secreted factors or continued juxtacrine signaling from
neighboring clones. Our data also show that highly proliferative
clones have the greatest fitness to regrow in a transplantation
setting, which may explain, in part, why relapsed cancers are
often more aggressive than primary disease.
Although we found that three of the six clones that evolved
increased LPC frequency acquired Akt pathway activation, we
were unable to pinpoint the precise mechanism of Akt pathway
activation in zebrafish, besides a correlation with loss of pten
expression and elevated expression of ras family members and
ptpn11a. In humans, the primary activator of Akt signaling is
likely PTEN inactivation, which occurs in >18% of T-ALL and is
associated with poor prognosis (Gutierrez et al., 2009). PTEN
deletion was also acquired upon relapse in 12% of matched pri-
mary and relapse patient xenograft samples, and PTEN knock-
down in a single primary human T-ALL provided a competitive
growth advantage and increased engraftment potential upon
xenograft transplant (Clappier et al., 2011), suggesting that
PTEN loss and Akt activation plays an important role in T-ALL
progression and relapse. Additionally, RAS is known to activate
the PI3K/Akt signaling cascade and is activated in a subset of
human T-ALL (Kawamura et al., 1999; Trinquand et al., 2013;
Zhang et al., 2012). Activation of the RAS pathway potently
induced T-ALL in mouse models, largely though activation of
the PI3K/Akt pathway (Kong et al., 2013; Shieh et al., 2013).
Together, these data suggest that the RAS and PI3K/Akt path-
ways may bemore commonly activated in T-ALL than previously
thought. As suggested by our data, Akt pathway activation likely
plays a critical role in human T-ALL progression by shortening
T-ALL latency and enhancing the overall frequency of LPCs con-376 Cancer Cell 25, 366–378, March 17, 2014 ª2014 Elsevier Inc.tained within the leukemia, both of which would provide a selec-
tive advantage to clones during disease progression and
relapse. Importantly, we observed that Akt signaling synergized
with both the Myc and intracellular notch1a oncogenes to drive
T-ALL progression in the zebrafish models, suggesting that the
Akt pathway likely collaborates with a variety of oncogenic
drivers to enhance LPC frequency in T-ALL. Finally, transgenic
epistasis experiments showed that Myc stabilization reduced
T-ALL latency while mTORC1 acts downstream of pAkt to regu-
late LPC frequency. Although it is well known that mTORC1 reg-
ulates normal hematopoietic stem cell self-renewal and has
prominent roles in leukemia initiation (Kalaitzidis et al., 2012), a
role for mTORC1 in regulating the frequency of LPCs in T-ALL
is largely unknown.
Acquired Akt pathway activation also rendered clonally
evolved T-ALL cells insensitive to dexamethasone, a gluco-
corticoid used as a front-line therapy for T-ALL. Remarkably,
inhibition of Akt or PI3K could restore sensitivity to dexametha-
sone-induced killing and specifically targets the LPC fraction.
While Akt pathway activation is known to render T-ALL cells
resistant to dexamethasone (Beesley et al., 2009; Chiarini
et al., 2010; Piovan et al., 2013), our data demonstrate that
T-ALL clones can also spontaneously develop chemotherapy
resistance without any prior exposure to drug. Thus, Akt path-
way activation is likely stochastically activated in a subset of
clones following continued clonal evolution and selected within
untreated, primary leukemias based on its role in elevating LPC
frequency and overall growth. Sadly, patients with clones that
have Akt pathway activation would likely already contain cells
that are insensitive to dexamethasone therapy. As an important
corollary, T-ALL clones found in patients undergoing dexameth-
asone therapy likely encounter extreme selection pressure to
activate the PI3K/Akt pathway in an effort to suppress responses
to dexamethasone. Once the PI3K/Akt pathway is activated,
T-ALL cells become simultaneously resistant to therapy, have
shortened latency, and have increased numbers of LPCs
capable of driving relapse. While MK2206 has met with limited
success in clinical trials for leukemia and solid tumors due to
toxicity issues (Yap et al., 2011), our data provide a strong ratio-
nale for utilizing PI3K/Akt inhibitors in preclinical testing against
T-ALL in combination with glucocorticoids, providing powerful
combinatory therapies that will eradicate T-ALL cells, reduce
the overall numbers of LPCs, and decrease T-ALL growth.EXPERIMENTAL PROCEDURES
Animal Use, Creation of Transgenic Zebrafish, and T-ALL
Transplantation
Zebrafish studies were approved by the Massachusetts General Hospital
Subcommittee on Research Animal Care, under protocol #2011N000127.
CG1-strain zebrafish were used exclusively for these studies. Creation of
mosaic transgenic animals and DNA constructs have been described previ-
ously (Blackburn et al., 2012) and are fully described in the Supplemental
Experimental Procedures. Because primary Myc-induced zebrafish T-ALL
contains, on average, <1 LPC per 100 FACS isolated cells (Smith et al.,
2010), monoclonal T-ALL could be generated from animals engrafted with
ten T-ALL cells and in some cases 100 cells. The statistical likelihood of gener-
ating T-ALL from a single LPC by 10- or 100-cell transplants is noted for each
clone in Table S1. Monoclonality was verified by detection of a single tcrb
rearrangement (Blackburn et al., 2012) (Table S1) and in some cases by array
CGH. Serial passaging of monoclonal T-ALL was accomplished using similar
Cancer Cell
Clonal Evolution Drives T-ALL Progressionprotocols as outlined previously (Blackburn et al., 2011). Kaplan-Meier ana-
lyses were performed using a Log-rank (Mantel-Cox) test in GraphPad Prism.
Analyses of limiting dilution cell transplantation data and calculation of 95%
confidence intervals were completed using Extreme Limiting Dilution Analysis
software (Hu and Smyth, 2009). All other statistical calculations were
completed using Student’s t test, except where noted.
Chemical Treatment of T-ALL Cells and T-ALL-Bearing Zebrafish
Human T-ALL cell lines were cultured as described (Blackburn et al., 2012) and
drug-treated as outlined in the Supplemental Experimental Procedures.
Ex vivo drug treatment of zebrafish T-ALL cells was completed using zebrafish
kidney stromal (ZKS) conditioned media as described the Supplemental
Experimental Procedures. For in vivo drug treatment, drugs were mixed in
zebrafish system water and animals submersed in drug containing water at
the doses and times described in the main text. Additional experimental con-
ditions are described in the Supplemental Experimental Procedures.
Immunohistochemistry, Western Blot Analysis, EDU Staining, Real-
Time Reverse Transcriptase PCR and Genomic DNA Sequencing
Paraffin embedding, sectioning and immunohistochemical analysis of zebra-
fish tissue were performed essentially as described (Langenau et al., 2003).
Antibodies and dilutions used for western blot analysis are noted in the Supple-
mental Experimental Procedures. EDU staining was performed using the
Click-iT Alexa Fluor 647 imaging kit (Invitrogen) according to manufacturer’s
protocol. Real-time reverse transcriptase PCR (RT-PCR) and sequencing of
genomic DNA was performed as previously described (Blackburn et al.,
2012), utilizing gene-specific primers (Supplemental Experimental Proce-
dures). Gene expression was normalized to ef1-a and b-actin controls to
obtain relative transcript levels using the 2DDCTmethod. For all analyses, cells
were isolated from fish with >50% T-ALL burden.
ACCESSION NUMBERS
The NCBI Gene Expression Omnibus accession number for the aCGH data
reported in this paper is GSE54482.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and four tables and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2014.01.032.
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